-
公开(公告)号:US20230302109A1
公开(公告)日:2023-09-28
申请号:US18046670
申请日:2022-10-14
发明人: George KASSIOTIS , George YOUNG , Jan ATTIG , Ambrosius SNIJDERS , David PERKINS , Fabio MARINO , Ray JUPP , Magdalena VON ESSEN , Peter MASON , Nicola TERNETTE
CPC分类号: A61K39/00119 , C07K14/4748 , A61P35/00 , A61K2039/876 , A61K2039/5158 , A61K2039/5154
摘要: There are disclosed inter alia antigen pools which are useful in the treatment of cancer, particularly melanoma, especially cutaneous melanoma and uveal melanoma.
-
公开(公告)号:US20230181745A1
公开(公告)日:2023-06-15
申请号:US18017347
申请日:2021-07-20
发明人: Richard Alexander Lewis , Jacqueline Hayles , Paul Nurse , Nicholas Edward Ellis Allenby , Jeffrey Errington
CPC分类号: A61K47/547 , A61P35/02 , A61K47/545
摘要: A zinc complex of a compound where the zinc complex is either a complex of JBIR-141 and a zinc ion and has the chemical formula C31H48N6O11Zn, or when the zinc complex is a complex of JBIR-142 and a zinc ion and has the chemical formula C31H48N6O12Zn.
-
3.
公开(公告)号:US20230099491A1
公开(公告)日:2023-03-30
申请号:US17936811
申请日:2022-09-29
申请人: CANCER RESEARCH TECHNOLOGY LIMITED , KING'S COLLEGE LONDON , THE FRANCIS CRICK INSTITUTE LIMITED
发明人: Adrian HAYDAY , Oliver NUSSBAUMER , Richard WOOLF
IPC分类号: C12N5/0783
摘要: This invention relates to the expansion of non-haematopoietic tissue-resident γδ T cells in vitro by culturing lympho-cytes obtained from non-haematopoietic tissue of humans or non-human animals in the presence of interleukin-2 (IL-2) and/or inter-leukin-15 (IL-15) and the absence of TCR activation or co-stimulation signals, without any direct contact with stromal or epithelial cells. Methods of non-haematopoietic tissue-resident γδ T cell expansion are provided, as well as populations of non-haematopoietic tissue-resident γδ T cells and uses thereof.
-
公开(公告)号:US20220213159A1
公开(公告)日:2022-07-07
申请号:US17644938
申请日:2021-12-17
发明人: George KASSIOTIS , George YOUNG , Jan ATTIG , Fabio MARINO
摘要: There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly melanoma, especially cutaneous melanoma and uveal melanoma.
-
公开(公告)号:US20210147942A1
公开(公告)日:2021-05-20
申请号:US16628070
申请日:2018-07-04
IPC分类号: C12Q1/6886 , A61K35/17 , C07K16/28
摘要: The present invention relates to a method for identifying a subject with cancer who is suitable for treatment with an immune checkpoint intervention, said method comprising analysing in a sample isolated from said subject the expressed frameshift indel mutational burden.
-
公开(公告)号:US20210147934A1
公开(公告)日:2021-05-20
申请号:US16628067
申请日:2018-07-13
申请人: THE FRANCIS CRICK INSTITUTE LIMITED , UNIVERSITY COLLEGE LONDON , CANCER RESEARCH TECHNOLOGY LIMITED
IPC分类号: C12Q1/6881 , C12Q1/6886 , A61K39/00 , C12Q1/6869
摘要: The present invention relates to a method for determining whether an HLA allele is lost in a tumour in a subject, wherein said method comprises the step of determining the specific copy number of said HLA allele in said tumour. The invention also relates to a method for treating cancer in a subject, comprising targeting a neoantigen which is predicted to be presented by an HLA molecule encoded by an HLA allele which has been determined not to have been lost in a tumour in said subject.
-
公开(公告)号:US10578620B2
公开(公告)日:2020-03-03
申请号:US16227899
申请日:2018-12-20
IPC分类号: G01N33/574 , G01N33/543
摘要: The present invention relates to a method for detecting molecules. The method employs: at least two primary antibodies, wherein the first primary antibody binds to a first site on a molecule and the second primary antibody binds to a second site on a molecule, wherein the second site is different from the first site and wherein the first and second primary antibodies are immunologically distinct; at least two secondary antibodies, wherein the first secondary antibody is labelled with a fluorescence resonance energy transfer (FRET) donor and binds to the first primary antibody; and the second secondary antibody is conjugated or fused to an enzyme and binds the second primary antibody, wherein the first secondary antibody does not bind the second primary antibody and the second secondary antibody does not bind the first primary antibody; a conjugate comprising a FRET acceptor and a substrate specific for the enzyme, wherein when the substrate reacts with the enzyme, an activated conjugate forms, which activated conjugate binds to electron rich moieties on a molecular surface adjacent to the enzyme; wherein the method comprises: contacting a sample with the at least two primary antibodies; contacting the sample with the at least two secondary antibodies; performing a wash step; contacting the sample with the conjugate; and detecting any FRET signal generated by the FRET acceptor.
-
公开(公告)号:US20180067075A1
公开(公告)日:2018-03-08
申请号:US15259435
申请日:2016-09-08
摘要: An electrochemical probe comprises a wire bundle including two or more wire electrodes made of conducting material arranged alongside each other, and insulating material surrounding the electrodes. An impedance reducing layer of metal or metal oxide nano-structures is deposited on tips of the wire electrodes at a first end of the bundle. A functionalization layer is deposited on the impedance reducing layer at the first end of the bundle. Such a probe is particularly useful for electrochemical sensing applications such as neuronal scanning.
-
公开(公告)号:US20240100161A1
公开(公告)日:2024-03-28
申请号:US18018685
申请日:2021-07-30
IPC分类号: A61K39/00 , C07K14/705 , C07K16/40
CPC分类号: A61K39/4633 , A61K39/4614 , A61K39/4622 , A61K39/4644 , C07K14/7056 , C07K16/40 , C07K2319/03
摘要: The present invention relates to chimeric receptors capable of facilitating cross-presentation (XP) of antigens, and methods of doing the same.
-
公开(公告)号:US20240002791A1
公开(公告)日:2024-01-04
申请号:US18039849
申请日:2021-12-08
发明人: Paola BONFANTI
CPC分类号: C12N5/0634 , A61L27/3813 , A61L27/3895 , A61L2430/40
摘要: The present invention provides a method of producing a thymic construct suitable for implantation into a subject, the method comprising the steps of: (i) providing an acellular scaffold; (ii) seeding the acellular scaffold with thymic epithelial cells having mesenchymal properties; and (iii) culturing the seeded scaffold to produce said construct. The thymic epithelial cells are preferably CD49f+ and may also be VIM+, TE-7+ and/or CD90+. The invention further provides pharmaceutical compositions, uses and therapies using thymic epithelial cells having mesenchymal properties.
-
-
-
-
-
-
-
-
-